Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325-e331.
Cron RQ, Chatham WW. The rheumatologist's role in COVID-19. J Rheumatol. 2020;47:639-642.
De Luca G, Cavalli G, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020;2:e465-e473.
Gupta S, Wang W, Hayek SS, et al; for the STOP-COVID Investigators. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.6252. [Epub ahead of print].
Hermine O, Mariette X, Tharaux P-L, et al. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2020. doi:10.1001/ jamainternmed.2020.6820. [Epub ahead of print].
Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2:e393-e400.
June CH, O'Connor RS, Kawalekar OU, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361-1365.
King A, Vail A, O'Leary C, et al. Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol. 2020;2:e379-e381.
Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594-e602.
Mehta P, Cron RQ, Hartwell J, et al. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2:e358-e367.
Mehta P, Porter JC, Manson JJ, et al. Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respir Med. 2020;8:822-830.
Montesarchio V, Parrela R, Iommelli C, et al. Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8:e001089.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473-474.
National Institute of Health. COVID-19 treatment guidelines. www.covid19treatmentguidelines.nih.gov/therapeutic-management. Accessed November 11, 2020.
Parr JB. Time to reassess tocilizumab's role in COVID-19 pneumonia. JAMA Intern Med. 2020. doi: 10.1001/jamainternmed.2020.6557. [Epub ahead of print].
Perrone F, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020;18:405.
Piccirillo MC, Ascierto P, Atripaldi L, et al. TOCIVID-19 -- a multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. Contemp Clin Trials. 2020;98:106165.
RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with COVID-19 -- preliminary report. N Engl J Med. 2020. doi: 10.1056/NEJMoa2021436. [Epub ahead of print].
RECOVERY trial website. This national clinical trial aims to identify treatments that may be beneficial for people hospitalised with suspected or confirmed COVID-19. Accessed September 1, 2020. https://www.recoverytrial.net/
F Hoffman-La Roche. Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. Accessed November 11, 2020. https://www.roche.com/media/releases/med-cor-2020-07-29.htm
F Hoffman-La Roche Ltd. Roche's phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood of needing mechanical ventilation in hospitalised patients with COVID-19 associated pneumonia. Published September 18, 2020. Accessed September 19, 2020. https:// www.roche.com/investors/updates/ inv-update-2020-09-18.htm
Royal College of Physicians website. Position Statement: Use of investigational immunomodulatory medicines for COVID-19. Published August 10, 2020. https://ctag-support.org.uk/docs/immunomodulators.pdf
Royal College of Physicians website. COVID-19 therapeutics advice & support group. Accessed November 11, 2020. https://www.ctag-support.org.uk/
Salama C, Han J, Yau L, et al. Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia. medRxiv 2020.10.21.20210203; doi: https://doi.org/10.1101/2020.10.21.20210203
Salvarani C, Dolci G, Massari M, et al; for the RCT-TCZ-COVID-19 Study Group. Effect of tocilizumab vs standard of care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2020. doi:10. 1001/jamainternmed.2020.6615. [Epub ahead of print].
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405-407.
Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med. 2020. doi: 10.1056/NEJMoa2028836. [Epub ahead of print].
Webb BJ, Peltan ID, Jensen P, et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study. Lancet Rheumatol. 2020. doi: 10.1016/S2665-9913(20)30343-X. [Epub ahead of print].
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330-1341.
World Health Organization. Corticosteroids for COVID-19. Accessed November 11, 2020. https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1
Writing Committee for the REMAP-CAP Investigators, Angus DC, Derde L, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA. 2020;324:1317–1329.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Ivan O. Rosas, MD

Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Disclosure: Ivan O. Rosas, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Genentech, Inc.
Received grants for clinical research from: Genentech, Inc.

Paolo A. Ascierto, MD

Director, Melanoma Unit
Cancer Immunotherapy and Innovative Therapy
National Tumor Institute Fondazione G. Pascale
Naples, Italy

Disclosures

Disclosure: Paolo A. Ascierto, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alkermes, Inc.; AstraZeneca Pharmaceuticals LP; Array; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Eisai Inc.; Idera; Immunocore; Incyte Corporation; Italfarmaco; MedImmune Inc.; Merck & Co., Inc.; Merck Serono; Nektar; Novartis Pharmaceuticals Corporation; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Roche-Genentech, Inc.; Sandoz; Sanofi; Sunpharma; Syndaz
Received grants for clinical research from: Array; Bristol Myers Squibb Company; Roche-Genentech, Inc.
Owns stock, stock options, or bonds from: Primevax

Puja Mehta, MD

Department of Rheumatology
University College London Hospital
London, United Kingdom

Disclosures

Disclosure: Puja Mehta, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Sobi
Received grants for clinical research from: GlaxoSmithKline

Editor

Shanthi Voorn, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

Cytokine-Targeted Therapy for Patients With COVID-19: From Guidelines to Latest Developments

Authors: Ivan O. Rosas, MD; Paolo A. Ascierto, MD; Puja Mehta, MD
CPD Released: 11/20/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 11/20/2021

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US critical care specialists, rheumatologists, and ID/HIV specialists.

The goal of this activity is to educate physicians on the current guideline recommendations regarding the use of cytokine-targeted therapies for patients with coronavirus disease 2019 (COVID-19) and the most recent clinical trial outcomes data with these drugs.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Current understanding of COVID-19-associated hyperinflammation
- Current treatment guidelines for severe or critically ill patients with COVID-19
- Latest evidence from clinical trials with immunomodulatory therapies for patients with COVID-19

Disclosures

Faculty

Ivan O. Rosas, MD

Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts, United States

Disclosures

Disclosure: Ivan O. Rosas, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Genentech, Inc.
Received grants for clinical research from: Genentech, Inc.

Paolo A. Ascierto, MD

Director, Melanoma Unit
Cancer Immunotherapy and Innovative Therapy
National Tumor Institute Fondazione G. Pascale
Naples, Italy

Disclosures

Disclosure: Paolo A. Ascierto, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Alkermes, Inc.; AstraZeneca Pharmaceuticals LP; Array; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Eisai Inc.; Idera; Immunocore; Incyte Corporation; Italfarmaco; MedImmune Inc.; Merck & Co., Inc.; Merck Serono; Nektar; Novartis Pharmaceuticals Corporation; Pierre Fabre; Regeneron Pharmaceuticals, Inc.; Roche-Genentech, Inc.; Sandoz; Sanofi; Sunpharma; Syndaz
Received grants for clinical research from: Array; Bristol Myers Squibb Company; Roche-Genentech, Inc.
Owns stock, stock options, or bonds from: Primevax

Puja Mehta, MD

Department of Rheumatology
University College London Hospital
London, United Kingdom

Disclosures

Disclosure: Puja Mehta, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Sobi
Received grants for clinical research from: GlaxoSmithKline

Editor

Shanthi Voorn, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Cytokine-Targeted Therapy for Patients With COVID-19: From Guidelines to Latest Developments

Authors: Ivan O. Rosas, MD; Paolo A. Ascierto, MD; Puja Mehta, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 11/20/2020

Valid for credit through: 11/20/2021

processing....

A Powerpoint version of the slides from this presentation
is available for use as a professional resource from Medscape Education.

Download Now

CPD Information

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Ivan O. Rosas, MD

Paolo A. Ascierto, MD

Puja Mehta, MD

Editor

Shanthi Voorn, PhD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CPD

Cytokine-Targeted Therapy for Patients With COVID-19: From Guidelines to Latest Developments

Target Audience and Goal Statement

Disclosures

Faculty

Ivan O. Rosas, MD

Paolo A. Ascierto, MD

Puja Mehta, MD

Editor

Shanthi Voorn, PhD

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Cytokine-Targeted Therapy for Patients With COVID-19: From Guidelines to Latest Developments